During the recent session, Seres Therapeutics Inc (NASDAQ:MCRB)’s traded shares were 0.55 million, with the beta value of the company hitting 1.95. At the last check today, the stock’s price was $0.76, reflecting an intraday gain of 0.76% or $0.01. The 52-week high for the MCRB share is $5.41, that puts it down -611.84 from that peak though still a striking 28.95% gain since the share price plummeted to a 52-week low of $0.54. The company’s market capitalization is $114.59M, and the average trade volume was 4.75 million shares over the past three months.
Seres Therapeutics Inc (NASDAQ:MCRB) trade information
Seres Therapeutics Inc (MCRB) registered a 0.76% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 0.76% in intraday trading to $0.76, hitting a weekly high. The stock’s 5-day price performance is 0.68%, and it has moved by -18.60% in 30 days. Based on these gigs, the overall price performance for the year is -85.56%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Seres Therapeutics Inc (MCRB) estimates and forecasts
Statistics show that Seres Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Seres Therapeutics Inc (MCRB) shares have gone down -43.54% during the last six months, with a year-to-date growth rate less than the industry average at -15.73% against 15.50.
As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 126.47M and 1.87M respectively.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 18.22%. While earnings are projected to return -17.43% in 2024.
MCRB Dividends
Seres Therapeutics Inc is due to release its next quarterly earnings in July. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
